SEARCH:   Advanced

Blood, 15 March 2007, Vol. 109, No. 6, pp. 2446-2452. Prepublished online as a Blood First Edition Paper on November 14, 2006; DOI 10.1182/blood-2006-08-042515. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-08-042515v1 109/6/2446    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Landolfi, R. Articles by Marchioli, R. Search for Related Content PubMed PubMed Citation Articles by Landolfi, R. Articles by Marchioli, R. Related Collections Hematopoiesis and Stem Cells Hemostasis, Thrombosis, and Vascular Biology Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Raffaele Landolfi1,2, Leonardo Di Gennaro1, Tiziano Barbui3, Valerio De Stefano1, Guido Finazzi3, RosaMaria Marfisi4, Gianni Tognoni4, Roberto Marchioli4, for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) 1 Catholic University School of Medicine, Rome, Italy; 2 Instituto di Ricovero e Cura e Carattera Scientifico Oasi Maria Santissima, Troina, Italy; 3 Ospedali Riuniti, Bergamo, Italy; 4 Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy In polycythemia vera, vascular risk assessment is based on age and thrombotic history, while the role of other potential predictors of this risk is still uncertain. Thus, we exploited the large database collected by the observational study of the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) to investigate the association of hematologic variables and cardiovascular risk factors with the thrombotic risk. Among 1638 polycythemic patients followed for 2.7 ± 1.3 years, there were 205 thromboses. Subjects with hypertension had a mild nonsignificant increase in the risk of arterial thrombosis, while this risk was significantly increased by smoking (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.15-3.14; P = .012). The time-dependent analysis adjusted for potential confounders showed that patients with a white blood cell count above 15 x 109/L, compared with those with a white blood cell count below 10 x 109/L, had a significant increase in the risk of thrombosis (HR, 1.71; 95% CI, 1.10-2.65; P = .017), mainly deriving from an increased risk of myocardial infarction (HR, 2.84; 95% CI, 1.25-6.46; P = .013). Thus, leukocyte count may help in defining the vascular risk of polycythemic subjects. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The granulocyte connection in MPD-associated thrombosis Ayalew Tefferi Blood 2007 109: 2270-2271. [Full Text] [PDF] This article has been cited by other articles: A. Quintas-Cardama, H. Kantarjian, T. Manshouri, R. Luthra, Z. Estrov, S. Pierce, M. A. Richie, G. Borthakur, M. Konopleva, J. Cortes, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera J. Clin. Oncol., November 10, 2009; 27(32): 5418 - 5424. [Abstract] [Full Text] [PDF] T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, July 23, 2009; 114(4): 759 - 763. [Abstract] [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] J. Malysz and D. Crisan Correlation of JAK2 V617F Mutant Allele Quantitation with Clinical Presentation and Type of Chronic Myeloproliferative Neoplasm Ann. Clin. Lab. Sci., January 1, 2009; 39(4): 345 - 350. [Abstract] [Full Text] [PDF] M. Marchetti, E. Castoldi, H. M. H. Spronk, R. van Oerle, D. Balducci, T. Barbui, J. Rosing, H. ten Cate, and A. Falanga Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera Blood, November 15, 2008; 112(10): 4061 - 4068. [Abstract] [Full Text] [PDF] J.-J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, B. Grandchamp, C. Chomienne, and P. Fenaux Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Blood, October 15, 2008; 112(8): 3065 - 3072. [Abstract] [Full Text] [PDF] R. L. Levine and D. G. Gilliland Myeloproliferative disorders Blood, September 15, 2008; 112(6): 2190 - 2198. [Abstract] [Full Text] [PDF] A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, G. Finazzi, A. Rambaldi, and T. Barbui Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia J. Clin. Oncol., June 1, 2008; 26(16): 2732 - 2736. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi Thrombophilia Screening: Little Role for the JAK2V617F Mutation Mayo Clin. Proc., April 1, 2008; 83(4): 398 - 399. [Full Text] [PDF] R. Landolfi and L. Di Gennaro Prevention of thrombosis in polycythemia vera and essential thrombocythemia Haematologica, March 1, 2008; 93(3): 331 - 335. [Full Text] [PDF] V. De Stefano, T. Za, E. Rossi, A. M. Vannucchi, M. Ruggeri, E. Elli, C. Mico, A. Tieghi, R. R. Cacciola, C. Santoro, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica, March 1, 2008; 93(3): 372 - 380. [Abstract] [Full Text] [PDF] R. A. Mesa Steel to heal? MPD surgical conundrums Blood, January 15, 2008; 111(2): 474 - 474. [Full Text] [PDF] M. Ruggeri, F. Rodeghiero, A. Tosetto, G. Castaman, F. Scognamiglio, G. Finazzi, F. Delaini, C. Mico, A. M. Vannucchi, E. Antonioli, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey Blood, January 15, 2008; 111(2): 666 - 671. [Abstract] [Full Text] [PDF] R. L. Levine and M. Heaney New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Hematology, January 1, 2008; 2008(1): 76 - 82. [Abstract] [Full Text] [PDF] G. Finazzi and T. Barbui How I treat patients with polycythemia vera Blood, June 15, 2007; 109(12): 5104 - 5111. [Abstract] [Full Text] [PDF] R. A. Mesa Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 355 - 362. [Abstract] [Full Text] [PDF] A. M. Vannucchi and T. Barbui Thrombocytosis and Thrombosis Hematology, January 1, 2007; 2007(1): 363 - 370. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020